This page provides comprehensive information about the topic.
Relyvrio (marketed as Relyvrio in US, Albrioza in Canada) is an FDA-approved dual-mechanism drug for amyotrophic lateral sclerosis (ALS) that combines sodium phenylbutyrate and taurursodiol.
The combination provides synergistic neuroprotection:
Protein Homeostasis
Mitochondrial Function
The study of Relyvrio (Sodium Phenylbutyrate Taurursodiol) For Als has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The CENTAUR trial (NCT03000196) was a randomized, double-blind, placebo-controlled Phase 2 study evaluating Relyvrio in ALS patients. The trial enrolled 137 participants with confirmed ALS diagnosis within 18 months of symptom onset. Participants were randomized 2:1 to receive Relyvrio or placebo for 24 weeks, followed by an open-label extension. The primary endpoint was change in ALSAQ-40 (ALSFRS-R) score at 24 weeks. While the study did not meet its primary endpoint at the initial analysis, prespecified analyses showed a statistically significant treatment effect in a subgroup of patients with less advanced disease.
Patients who completed the randomized phase were eligible to enroll in an open-label extension where all participants received Relyvrio. Long-term follow-up data showed that patients who received Relyvrio earlier in the randomized phase had better outcomes than those who initially received placebo and then switched to active treatment. This suggested that earlier intervention with Relyvrio may provide more benefit.
The Phase 3 HEALEY ALS trial (NCT05021536) was a registration-enabling study that evaluated Relyvrio at the approved dose in a larger patient population. This multi-site trial used a seamless adaptive design allowing for interim analyses. The trial enrolled patients with clinically definite, probable, or laboratory-supported ALS diagnosed within 24 months of symptom onset.
Following oral administration, both sodium phenylbutyrate and taurursodiol are absorbed through the gastrointestinal tract. Peak plasma concentrations are achieved within 1-2 hours for phenylbutyrate and 2-4 hours for taurursodiol. Food may reduce the rate but not the extent of absorption.
Sodium phenylbutyrate is highly protein-bound and distributes throughout the body including the central nervous system. Taurursodiol has moderate protein binding and undergoes enterohepatic recirculation, which extends its half-life. Both compounds can cross the blood-brain barrier, though their CNS concentrations relative to plasma have not been fully characterized.
Phenylbutyrate is primarily metabolized by hepatic beta-oxidation to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine, excreted in urine. Taurursodiol undergoes conjugation with glycine and taurine in the liver. The metabolites are primarily eliminated renally.
The most frequently reported adverse reactions in clinical trials included diarrhea, nausea, abdominal pain, and upper respiratory tract infections. These gastrointestinal symptoms often occur early in treatment and may improve with continued therapy. Dose adjustments may be needed for patients experiencing persistent GI side effects.
In the clinical trials, serious adverse events were similar between Relyvrio and placebo groups. These included respiratory complications, which are common in ALS patients regardless of treatment. Monitoring of respiratory function is recommended for all ALS patients.
Both components of Relyvrio are metabolized hepatically, and monitoring of liver enzymes is recommended periodically during treatment. Patients with pre-existing liver disease may require additional monitoring and dose adjustments.
Relyvrio joins riluzole and edaravone as FDA-approved disease-modifying therapies for ALS. These treatments have different mechanisms of action and can potentially be used in combination. Relyvrio's mitochondrial protective mechanism is distinct from riluzole's glutamate modulation and edaravone's antioxidant effects, providing a complementary therapeutic approach.
Research is ongoing to identify patient subgroups most likely to benefit from Relyvrio treatment. Biomarker studies are examining whether specific genetic or metabolic signatures predict response. Combination trials evaluating Relyvrio with other ALS therapies are planned.